Cover Image

Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Objective: We aimed to evaluate the efficacy of canagliflozin for the treatment of specific cardiovascular and renal outcomes in Type 2 diabetes mellitus (T2DM) patients by means of a systematic review and meta-analysis.Methods: We performed comprehensive searches of PubMed, the Cochrane Library, an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lei Tian (Author), Yuzi Cai (Author), Huijuan Zheng (Author), Sinan Ai (Author), Mengqi Zhou (Author), Qian Luo (Author), Jingyi Tang (Author), Weijing Liu (Author), Yaoxian Wang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
by: Lei Tian, et al.
Published: (2022)

Global research trends and hot spots on autophagy and kidney diseases: a bibliometric analysis from 2000 to 2022
by: Sinan Ai, et al.
Published: (2023)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
by: Syed Raza Shah, et al.
Published: (2018)

Canagliflozin - Beginning of the journey
by: Sunil Kumar Pandey, et al.
Published: (2014)

Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease
by: Xueliang Wang, et al.
Published: (2022)

Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway
by: Wenhui Hao, et al.
Published: (2023)

Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016)

Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018)

Emerging treatments in type 2 diabetes: focus on canagliflozin
by: Rosiak M, et al.
Published: (2014)

EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
by: Rishad Ahmed, et al.
Published: (2017)

Patient profiling in diabetes and role of canagliflozin
by: Amblee A
Published: (2014)

Canagliflozin: a novel treatment option for type 2 diabetes
by: Dietrich E, et al.
Published: (2013)

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
by: Boyu Li, et al.
Published: (2018)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway
by: Zhao Y, et al.
Published: (2021)

Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1α inhibition
by: Jian Wang, et al.
Published: (2023)

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
by: Ghazaleh Behnammanesh, et al.
Published: (2019)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
by: Xingyun Hou, et al.
Published: (2019)

Thonningianin A ameliorated renal interstitial fibrosis in diabetic nephropathy mice by modulating gut microbiota dysbiosis and repressing inflammation
by: Shujiao Zhang, et al.
Published: (2024)

Canagliflozin-induced pancreatitis: a rare side effect of a new drug
by: Chowdhary M, et al.
Published: (2015)

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats
by: Takahiro Oguma, et al.
Published: (2015)

Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure
by: Ahasanul Hasan, et al.
Published: (2022)

Study on consequences for interaction of myricetin with canagliflozin: A special attention to pharmacokinetics and pharmacodynamics of drug
by: Naga Raju Kandukoori, et al.
Published: (2023)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
by: Daniel A. Kelmenson MD, et al.
Published: (2017)

Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes
by: Eiji Kutoh, et al.
Published: (2018)

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
by: Cankun Zheng, et al.
Published: (2022)

Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report
by: Christopher Bowman MD, et al.
Published: (2017)

Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice
by: Zuo Q, et al.
Published: (2022)

The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
by: Linda A. Villani, et al.
Published: (2016)

Double‐blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study
by: Sangeeta R. Kashyap, et al.
Published: (2020)

Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison
by: David Cherney, et al.
Published: (2024)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
by: Victor Sokolov, et al.
Published: (2020)

Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials
by: Pravesh Kumar Bundhun, et al.
Published: (2017)

Integrating network pharmacology and experimental validation to decipher the mechanism of the Chinese herbal prescription modified Shen-Yan-Fang-Shuai formula in treating diabetic nephropathy
by: Borui Yu, et al.
Published: (2023)

Canagliflozin Inhibits Palmitic Acid-Induced Vascular Cell Aging In Vitro through ROS/ERK and Ferroptosis Pathways
by: Fang Wan, et al.
Published: (2024)

Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1
by: Yaoyun Niu, et al.
Published: (2022)

Canagliflozin alleviates valproic acid-induced autism in rat pups: Role of PTEN/PDK/PPAR-γ signaling pathways
by: Mariam A. Elgamal, et al.
Published: (2023)

Canagliflozin Ameliorates Oxidative Stress and Autistic-like Features in Valproic-Acid-Induced Autism in Rats: Comparison with Aripiprazole Action
by: Mohammed Moutaz Nakhal, et al.
Published: (2023)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease
by: Gabriela Dumitrita Stanciu, et al.
Published: (2023)